Factor 12 deficiency, or activator of non-activated plasma prothrombin deficiency, is a rare genetic condition associated with hemostasis disorder caused by a lack of factor XII of the coagulation system. This factor, also known as Hageman factor, plays a key role in the activation of the coagulation cascade, in addition to its involvement in the inflammatory and fibrinolytic systems. Although its deficiency does not usually lead to significant thrombotic events, it can manifest as a predominantly hemorrhagic state, which requires adequate clinical monitoring and support.
History of the disease and interesting historical facts
Factor 12 deficiency was first described in 1955 when researchers noticed that some patients with bleeding disorders had abnormalities in the clotting system but did not respond to standard treatment. This paradox led to a more in-depth study of clotting factors, which helped to isolate factor XII as a separate component. Interestingly, Hageman, after whom the factor is named, was the first to emphasize its biological activity. Modern research shows that patients with factor XII deficiency may have a high susceptibility to thrombosis despite having low levels of the factor.
Epidemiology
Factor 12 deficiency is a rare disorder and its prevalence varies by region. Statistics indicate that in some populations the incidence of the condition may be as high as 1:1,000,000. While most cases are sporadic, familial transmission has been reported, suggesting that the disorder may be hereditary. For example, in studies conducted in the United States, fewer than 5% patients with hemorrhagic syndromes had low levels of factor XII, highlighting its rarity.
Genetic predisposition to this disease
Factor 12 deficiency is inherited in an autosomal recessive manner. The F12 gene, responsible for the synthesis of factor XII, is located on chromosome 5. In most cases, various mutations are detected in this gene, leading to a decrease in the synthesis of the factor or its inactive form. The most common mutations include point mutations, insertions and deletions, which change the structure of the protein, which in turn complicates the normal functioning of the factor. Familial cases are usually confirmed by molecular genetic testing, which can identify carriers of the gene, which is important for early detection and diagnosis.
Risk factors for the development of this disease
Factor XII deficiency is mostly a hereditary condition, but there are factors that can contribute to its occurrence. These include:
- Hereditary predisposition in families with a history of hemorrhagic disorders.
- Environmental factors, such as exposure to chemicals or toxins, that may interfere with the synthesis of clotting factors.
- Certain underlying medical conditions that may interfere with the metabolism of vitamins or minerals needed for the normal functioning of the blood clotting system.
Diagnosis of this disease
Major symptoms of factor XII deficiency may include:
- Frequent nosebleeds.
- Prolonged bleeding after injury or surgery.
- Hemorrhages after menstruation in women.
Laboratory tests to diagnose factor XII deficiency include:
- A coagulogram analysis that studies the activated partial thromboplastin time (APTT).
- Factor XII level test and other clotting tests.
Radiological examinations are generally not essential in cases of factor XII deficiency, but can be used to exclude other pathologies.
Differential diagnosis is necessary to exclude other types of hemorrhagic conditions such as hemophilia, thrombocytopenic purpura, and vascular anomalies.
Treatment
Treatment for factor XII deficiency varies depending on the severity of bleeding symptoms. General approaches include:
- Replacement therapy with coagulation factors in case of severe hemorrhages.
- Local treatment to stop minor bleeding.
Pharmacological treatment may include:
- Sodium cromoglycate to reduce the risk of blood clots.
- Drugs that improve platelet aggregation.
Surgical treatment is necessary in cases of severe bleeding where the source of bleeding must be eliminated. Other treatments may include physical rehabilitation to prevent re-injury.
List of medications used to treat this disease
- Sodium cromoglycate
- Dapagliflozin
- Fibrinolyticum
- Aspirin for the prevention of blood clots
Disease monitoring
Control steps for monitoring factor XII deficiency include regular determination of coagulation factor levels, assessment of clinical changes, and management of thrombotic risks. The prognosis of the disease is usually good with proper diagnosis and treatment. Potential complications may include thrombotic events, which require careful monitoring and prevention.
Age-related features of the disease
Factor XII deficiency can manifest itself at any age, but in children these manifestations may be less pronounced, while in adults more severe forms of hemorrhage are observed. Elderly patients have a higher risk of thrombosis, requiring special monitoring and prevention.
Questions and Answers
- What is the main symptom of factor XII deficiency? The main symptom is frequent nosebleeds and prolonged wounds.
- Can factor XII defect be detected by blood tests? Yes, the level of factor XII can be determined by coagulograms.
- What is the danger of factor XII deficiency? The main danger lies in the high predisposition to thrombosis.
- How is factor XII deficiency treated? Treatment includes replacement therapy, anticoagulants and local treatment to stop bleeding.
- Who should be tested for factor XII deficiency? Testing is recommended for individuals with a hereditary predisposition to hemorrhagic disorders.
Advice from Dr. Oleg Korzhikov
Dr. Oleg Korzhikov suggests paying attention to regular monitoring of the condition, especially if there is a hereditary predisposition. “Do not forget about the potential risks associated with thrombosis, especially in people over 60. It is important to monitor symptoms and contact a doctor if they occur. Make sure that your loved ones are aware of your condition so that they can respond in time if necessary,” he recommends.
